EW240517C45000
- 40.80
- 0.000.00%
Edwards Lifesciences Newsroom
Citi Upgrades Edwards Lifesciences(EW.US) to Buy Rating, Raises Target Price to $105
Citi analyst Joanne Wuensch upgrades $Edwards Lifesciences(EW.US)$ to a buy rating, and adjusts the target price from $98 to $105.According to TipRanks data, the analyst has a success rate of 62.2% an
Express News | NYSE Order Imbalance 80831.0 Shares on Sell Side
Citi Upgrades Edwards, Tandem; Cuts Nevro, Establishment Labs
Should You Investigate Edwards Lifesciences Corporation (NYSE:EW) At US$90.34?
Edwards Lifesciences Corporation (NYSE:EW) received a lot of attention from a substantial price movement on the NYSE over the last few months, increasing to US$95.56 at one point, and dropping to the
Express News | Edwards Lifesciences Corp : Citigroup Raises Target Price to $105 From $98
Express News | Edwards Lifesciences Corp : Citigroup Raises to Buy From Neutral
Express News | Edwards Lifesciences Shares up 1.8% Premarket After Citi Upgrades to Buy From Neutral
Citigroup Upgrades Edwards Lifesciences to Buy From Neutral, Adjusts Price Target to $105 From $98
Edwards Lifesciences (EW) has an average rating of outperform and price targets ranging from $73 to $105, according to analysts polled by Capital IQ. Price: 91.00, Change: +0.66, Percent Change: +0.73
Edwards Lifesciences(EW.US) Officer Sells US$508.8K in Common Stock
$Edwards Lifesciences(EW.US)$ Officer Ullem Scott B. sold 5,625 shares of common stock on May 21, 2024 at an average price of $90.4539 for a total value of $508.8K.Source: Announcement What is stateme
Express News | NYSE Order Imbalance 74336.0 Shares on Buy Side
A Fantastic Week for Edwards Lifesciences Corporation's (NYSE:EW) 84% Institutional Owners, One-year Returns Continue to Impress
Robust Growth and R&D Focus Solidify Buy Rating for Edwards Lifesciences
Express News | NYSE Order Imbalance 70696.0 Shares on Sell Side
Express News | NYSE Order Imbalance 82717.0 Shares on Sell Side
Here's How Much $1000 Invested In Edwards Lifesciences 15 Years Ago Would Be Worth Today
Edwards Lifesciences (NYSE:EW) has outperformed the market over the past 15 years by 8.32% on an annualized basis producing an average annual return of 20.89%. Currently, Edwards Lifesciences has a ma
Express News | NYSE Order Imbalance 121493.0 Shares on Buy Side
Edwards Lifesciences Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/14/2024 20.67% Deutsche Bank $86 → $103 Upgrades Hold → Buy 05/07/2024 18.32% Barclays $100 → $101 Main
Edwards Lifesciences: A Buy Rating With Strong Growth Prospects and Positive Market Dynamics
Express News | Edwards Lifesciences Corp : Deutsche Bank Raises Target Price to $103 From $86
Express News | Edwards Lifesciences Corp : Deutsche Bank Raises to Buy From Hold